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Abstract Migraine and stroke are common, disabling neuro-
logic disorders, with a high socioeconomic burden. A link
between them has been proposed years ago, and various the-
ories have been proposed to explain this bidirectional relation.
However, the precise causes remain unclear. We briefly sum-
marize existing hypotheses of this correlation seeking for rec-
ommendations for stroke prevention in migraineurs, if any
exist. Among the strongest suggested theories of migraine–
stroke association are cortical spreading depression,
endovascular dysfunction, vasoconstriction, neurogenic in-
flammation, hypercoagulability, increased prevalence of vas-
cular risk factors, shared genetic defects, cervical artery dis-
section, and patent foramen ovale. There is no evidence that
any preventive therapy in migraineurs should be used to de-
crease stroke risk, even in most predisposed subset of patients.
However, a womanwith migraine with aura should be encour-
aged to cease smoking and avoid taking oral contraceptives
with high estrogen doses. We need further investigation to
better understand the complexity of migraine–stroke associa-
tion and to make firm recommendations for the future.
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Introduction
A complex association between migraine and stroke has been
discussed for over 40 years [1]. These 2 diseases, one seem-
ingly benign and the second often severe and catastrophic,
remain common neurologic disorders with a high socioeco-
nomic burden [2•]. Stroke is the second most common cause
of death worldwide and the third most common cause of dis-
ability [3, 4]. The prevalence of all strokes in adults has been
estimated at 2.9% with unclear predominance among men [5,
6]. Migraine affects about 13% of the population and the
prevalence of the disease is highest in women in reproductive
ages [7, 8]. Numerous epidemiologic studies report that an
overall number of stroke patients, stroke related death and
global burden of stroke have an increasing tendency [2•]. It
is also observed in a population of migraineurs [9]. Emerging
evidence indicates that migraine is associated with white mat-
ter lesions, cardiac events and vascular diseases as well
[10–12]. Among cardiovascular diseases occurring more fre-
quently in migraineurs are hypertension, Reynaud’s syn-
drome, ischemic heart disease and myocardial infarction, co-
morbidities which often accompany stroke [13–15]. A recent
large prospective cohort study revealed that migraine in-
creases the risk of myocardial infarction (hazard ratio [HR]
1.39), stroke (HR 1.62), angina/coronary revascularization
procedures (HR 1.73), and cardiovascular mortality (HR
1.37) [13]. There is some evidence supporting the clinical
association between migraine and hemorrhagic stroke and be-
tween migraine and transient ischemic attacks [16, 17], but a
discrepancy in the literature over the strength and significance
of this relationship still remains, as other studies show no
association [18]. Undoubtedly the association between mi-
graine and ischemic stroke is the strongest. The percentage
of cryptogenic ischemic stroke in migraineurs tends to be
higher than in controls.
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Migraine-Related Stroke, Migraine Infarction,
and White Matter Hyperintensities
Up to a third of migraineurs experience transient neuro-
logic symptoms called aura, before or during headache
[19]. The risk of stroke is twice as high in migraine with
aura patients, both between (migraine related stroke) and
during attacks (migraine infarction) [20–22]. On the other
hand, most studies revealed that migraine without aura
does no t inc rease the r i sk of s t roke [11 , 23] .
Undoubtedly there is a correlation between the frequency
of migraine attacks and the risk of stroke [11, 24]. Stroke
Prevention in Young Women study revealed a higher
stroke risk among women having more than 12 attacks
per year [25]. It has also been demonstrated that the
stroke risk among migraineurs is elevated in women,
among smokers, in women taking oral contraceptive pills,
with recent onset of migraine, and in patients younger
than 45 [11]. Interestingly, in a population aged 65+
non-migrainous headache, rather than migraine, may be
the risk factor for stroke [26]. Migraine infarction is a
complication of an attack of migraine with aura. It is an
uncommon condition. It occurs with the prevalence 1.4–
3.4/100 000, which is 0.2%–0.5% of all ischemic strokes
[27, 28]. According to the International Classification of
Headache Disorders (ICHD)-3, migrainous infarction is
defined as an attack of migraine with aura in which one
or more aura symptoms last more than 60 minutes and
neuroimaging demonstrates an ischemic brain lesion in
the relevant territory. It mostly affects young women with
a history of migraine with aura [29]. Studies show 65%–
82% of migraine infarction cases are located in the pos-
terior circulation, mostly in the cerebellum [27–31]. There
are data revealing that the cerebellum is more vulnerable
in migraineurs, particularly with aura, and in familial
hemiplegic migraine [32]. Acute ischemic lesions are usu-
ally multiple, round- or oval-shaped, with a mean diame-
ter of 7 mm, and located in different arterial areas [27, 28,
31]. Magnetic resonance imaging of migraine brain, par-
ticularly T2 –weighted and FLAIR sequences, often re-
veal small, usually multiple hyperintensities, typically lo-
cated periventricularly or in the deep white matter, which
are called white matter lesions (WML) [33, 34]. WML are
not specific to migraine; however, their prevalence ranges
from 4% to 59% of migraine population, which is signif-
icantly higher than in controls [35]. The exact etiology
and clinical significance of these abnormalities remains
uncertain. Some data show that the intensification of these
abnormalities increases with migraine frequency (in those
with ≥1 attack/month OR = 2.6; 95% CI 1.2–6.0) (26
Kruit 2010). A study evaluating if cognitive decline could
be related to WML failed to find any association; howev-
er, there are reports indicating an enhanced risk of stroke
with increase in WML volume [36]. Further investigation
is needed, considering that fact that we can speculate that
brain structural changes in migraine could serve as disease
biomarkers and help to evaluate the risk of stroke in the
future.
The Underlying Mechanisms of Coincidence
Migraine and Stroke
The pathogenic mechanisms explaining the migraine–stroke
association remain poorly understood, but a few hypotheses
exist. Among suggested theories of migraine–stroke relation
are cortical spreading depression, vasoconstriction,
endovascular dysfunction, increased prevalence of vascular
risk factors, shared genetic defects, cervical artery dissection,
cardiac abnormalities including patent foramen ovale (PFO),
neurogenic inflammation, and hypercoagulability [11, 19,
37–43].
Cortical Spreading Depression
Cortical spreading depression (CSD) is the electrophysiolog-
ical mechanism that underlies migraine aura [44]. Also, it
plays a role in the pathogenesis of ischemic stroke, intracranial
hemorrhage, subarachnoid hemorrhage, traumatic brain inju-
ry, transient global amnesia, and some other diseases [45–47].
CSD is a potent, self- propagating, short-lasting depolarization
wave that moves across the cortex at a rate of 3–5 mm/min
[48]. By activation of metalloproteinases, CSD changes the
permeability of the blood–brain barrier [49]. Therefore, it is
associated with significant ionic and water changes and large
transient increase in energy metabolism [50]. Higher oxygen
and glucose expenditure accompanying CSD raises cerebral
blood flow [47, 51]. Cerebral hyperemia is followed by
prolonged cerebral oligaemia attributable to decreased vascu-
lar responsiveness [52]. Therefore, it may favor ischemic
events in the brain [53]. In addition, in vulnerable tissue, se-
vere hypoperfusion may follow CSD, consequently leading to
enlargement of ischemic lesion [54]. Mice with human mi-
graine mutations represent an increased vulnerability to CSD
and cerebral ischemia [37, 53]. It may be speculated that CSD
could be the mechanism causing the ischemic lesion in the
vulnerable brain.
The Role of Endothelium
The role of endothelium in migraine pathogenesis and
migraine-associated stroke has been raised during the past
decades [55]. Endothelium participates in homeostasis
influencing a vascular reactivity, but also thrombolysis,
thrombosis, proliferation, and apoptosis [56]. Microparticles
released from endothelial cells lead to endothelial activation
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and dysfunction [57]. Among endothelial biomarkers of in-
jured endothelium are vascular endothelial growth factor, t-
PA, von Willebrand factor, C-reactive protein, reduced nitrate
levels, all of which were found in migraineurs, some only in
migraineurs with aura [58, 59]. Inflammatory cytokines re-
leased in the aura phase activate the endothelium leading to
procoagulatory and prothrombotic state [55]. However, re-
search of cerebrovascular reactivity in migraineurs has dem-
onstrated conflicting data (decreased or increased cerebral
vascular reactivity) in regard to the causal relationship of en-
dothelium dysfunction in stroke pathogenesis [60–62].
Cardiovascular RF
Migraineurs are at the heightened risk of various types of
vascular events including stroke [63]. For this reason, stroke
risk factors in migraineurs have been widely evaluated in the
literature. Regarding hypertension, which may impair cerebral
blood flow and cause alterations in cerebral artery structure,
we find studies indicating the incidence of high blood pressure
is higher in migraine patient and contradictory evidence from
other research [64–68]. Similarly, the data about the relation-
ship of migraine and obesity are inconsistent. Most studies
show that obesity increases the risk of having migraine and
the risk grows with increasing BMI [69, 70]. Total body obe-
sity may impact migraine frequency, severity, and duration
[71]. Subsequently, a large body of evidence has highlighted
an involvement of obesity in migraine chronification [70–72].
The majority of available studies indicate that there is a pos-
itive correlation between cigarette smoking and migraine, re-
vealing that the number of smokers among migraineurs is
significantly higher compared with healthy controls [72–74].
Smoking among migraineurs seems to be related to the devel-
opment of cranial autonomic symptoms, but evidence indicat-
ing that tobacco use may trigger headache is lacking [75, 76].
However, Coronary Artery Risk Development in Young
Adults (CARDIA) Study demonstrated an increased risk of
developing migraine in young smokers [77]. Studies on the
role of dyslipidemia in migraine patients are quite homoge-
nous and demonstrate an association between unfavorable
cholesterol profile and migraine, particularly with aura [14].
Fewer studies failed to demonstrate the association between
dyslipidemia and migraine or showed negative association
[72, 78]. Based on the available data, we cannot indicate any
single risk factor that could play a predominant role in the
pathogenesis of stroke in migraineurs.
Patent Foramen Ovale
Patent foramen ovale (PFO) is linked to cryptogenic stroke
and transient ischemic attacks in a mechanism of paradoxical
embolism and transient hypoxemia [79–81]. Many, but not all
available studies report there is a higher prevalence of PFO in
migraineurs, especially with aura [82–86]. Wolff reported
64.7% of migrainous infarction patients have persistent fora-
men ovale [28]. As demonstrated by Larossa, PFO is not more
common or larger in chronic migraine than in episodic mi-
graine patients [85]. In a subset of migraineurs with stroke,
prevalence of PFO was significantly higher and the mean age
of stroke was lower than in controls [87]. Numerous observa-
tional studies report positive impact of PFO closure on the
occurrence of migraine [88–91]. However, the balance be-
tween risks and benefits is not favorable enough; therefore,
the routine detection and closure of PFO for migraine preven-
tion is not recommended [84, 92, 93].
Underlying Genetic Disorders
The complexity of the migraine and stroke correlation is seen
in genetic vasculopathies such as cerebral autosomal domi-
nan t a r te r iopa thy wi th subcor t ica l in fa rc t s and
leukoencephalopathy (CADASIL). Mitochondrial encepha-
lopathy with lactic acidosis and stroke (MELAS),
cerebroretinal vasculopathy, and hereditary endotheliopathy
with retinopathy, nephropathy and stroke (HERNS) are other
genetic disorders connecting migraine and stroke-like epi-
sodes; however, these interesting topics remain beyond the
scope of this article. Apart from these disorders, other genetic
factors seem to play a role in the discussed correlation. Data
from a recent, large, genome-wide analysis study indicate that
the strongest genetic overlap exists between migraine without
aura and large artery stroke, and cardio-embolic stroke [94].
Genetic factors do not seem to play an important role in a
shared pathogenesis of stroke and migraine with aura [94].
Cerebral Autosomal Dominant Arteriopathy
with Subcortical Infarcts and Leukoencephalopathy
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASI) is an autosomal
dominant disease caused by rare mutations of the gene
encoding the neurogenic locus notch homolog protein 3
(NOTCH 3 gene) located on chromosome 19p13 [95]. The
gene encodes a vascular smooth muscle cells receptor. Its
defect leads to chronic white matter ischemia due to non-
artheriosclerotic, non-amyloid vasculopathy with fibrosis
and an accumulation of granular and osmiophilic substances
perforating cerebral arteries [96, 97]. Stroke risk among these
patients is enhanced. It should be suspected when a patient has
one or more of recurrent subcortical ischemic strokes at the
mean age of 45 years, especially in the absence of other risk
factors, migraine (typically with aura) and/or early cognitive
decline, or subcortical dementia usually associated with
pseudobulbar palsy [34, 98]. Migraine, typically with aura,
occurs in about 30% of patients. It is usually the earliest symp-
tom, and in some patients the only clinical manifestation of the
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disease [98]. In most cases attacks of migraine improve or
cease when other manifestations of CADASIL (e.g., ischemic
stroke) appear [29]. Magnetic resonance imaging is always
abnormal with well delineated, small, bilateral infarcts typi-
cally seen in the deep white matter and in the periventricular
region predominantly in the frontal, parietal and anterior tem-
poral lobes, rarely in the occipital lobes [99].
Familial hemiplegic migraine (FMH) is a rare (5/100 000),
autosomal dominant disease, the subtypes of which are caused
by mutation on the CACNA1A, ATP1A2, SCN1A or PRRT2
genes [34, 100, 101]. FHM is characterized by reversible mo-
tor weakness, which may resemble stroke or transient ische-
mic attack [29]. Studies indicate that FHM increases suscep-
tibility to spreading depression and enhances ischemic vulner-
ability of migraine brain [102].
Migraine Drugs
Migraine specific drugs, triptans and ergotamines, may induce
vasoconstriction that putatively could enhance stroke risk
[103]. Several studies on triptan safety reveal conflicting re-
sults, so no firm conclusion can be drawn [104, 105].
However, by analyzing the available data we may speculate
that even if the absolute risk of stroke is enhanced in patients
recently exposed to triptans, the risk is small and estimated at
1:100,000 treated attacks for sumatriptan [106]. Therefore, in
light of current knowledge, minding their effectiveness in
treating migraine we should always take triptans into consid-
eration as a treatment option. As migraine is a disorder that
particularly concerns young woman in the fertile period of
life, contraceptive pills are often required [107].
Furthermore, in menstrual related migraine, stabilizing estro-
gen level by use of contraceptive pills may decrease the inten-
sity and duration of menstrual related migraine attacks [108,
109]. Some headache specialists are still cautious with their
use for fear of increasing stroke risk. Most of the past studies
evaluating the effect of oral contraceptive pills on the course
of migraine and stroke risk were based on high dose estrogen
pills 50 to 100 mcg of ethynyl estradiol. Current evidence
demonstrates that new, low-dose oral contraceptives (25 mcg
of ethynyl estradiol or less) do not enhance vascular risk in
migraine woman [110].
Conclusions
A large body of evidence supports the link between migraine
and ischemic stroke. The subset of patients at the most in-
creased risk of stroke are young females with migraine with
aura and patients suffering from genetic disorders like
CADASIL, MELAS, and HERNS. A 2-fold increased risk
of ischemic stroke in migraine with aura patients has been
noted in some population-based studies [22, 29, 111].
Migraineurs, particularly at heightened risk of stroke, should
be encouraged to manage other risk factors for stroke, like
hypertension, diabetes, obesity, elevated homocysteine, and
dyslipidemia, as it seems to be a reasonable approach to de-
crease the overall risk of stroke. A firm recommendation not
to smoke should be made. Evidence suggests that we should
not be afraid of using low-estrogen contraceptives in females
with migraine, especially when non-hormonal preventive
treatment has been unsuccessful [107, 112]. A firm correlation
between the frequency of migraine attacks and the risk of
stroke exists; however, there are no data indicating that mi-
graine prophylaxis decreases the risk of migrainous infarct
[113]. Keeping in mind the aspect of quality of life in
migraineurs, we should always consider use of migraine-
specific abortive drugs, remembering that in female
migraineurs the absolute risk of stroke is low [114].
Considering that we lack sufficient proof to justify any of
the known factors having a predominant role in migraine
stroke relation, further investigation is a necessary. It should
focus on answering the question whether stroke in migraine
with aura patients might be prevented, and by which therapeu-
tic strategies.
Compliance with Ethical Standards
Conflict of Interest Anna Gryglas and Robert Smigiel declare that they
have no conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Harriott AM, Barrett KM. Dissecting the association between mi-
graine and stroke. Curr Neurol Neurosci Rep. 2015;15:5.
2.• Mawet J, Kurth T, Ayata C. Migraine and stroke: in search of
shared mechanisms. Cephalalgia. 2015;35:165–81. This extend-
ed literature review article reveals recent clinical evidence
linkingmigraine and stroke. In the light of current knowledge,
it clarifies the mechanisms of association between migraine
and stroke, opportunities for the risk factor screening, man-
agement of acute stroke, and stroke prophylaxis.
3. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA,
Connor M, Bennett DA, et al. Global and regional burden of
22 Page 4 of 7 Curr Neurol Neurosci Rep (2017) 17: 22
stroke during 1990–2010: findings from the Global Burden of
Disease Study 2010. Lancet. 2014;383:245–54.
4. Global Health Estimates. Geneva: World Health Organization;
2012. Available at: http://www.who.int/healthinfo/global_
burden_disease/en/Accessed October 2, 2016.
5. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha
MJ, et al. Heart disease and stroke statistics-2014 update: a report
from the American Heart Association. Circulation. 2014;129:28–
292.
6. Barker-Collo S, Bennett DA, Krishnamurthi RV, Parmar P, Feigin
VL, Naghavi M, et al. Sex differences in stroke incidence, preva-
lence, mortality and disability-adjusted life years: results from the
Global Burden of Disease Study 2013. Neuroepidemiology.
2015;45:203–14.
7. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine
prevalence by age and sex in the United States: a life-span study.
Cephalalgia. 2010;30:1065–72.
8. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and
burden of migraine and severe headache in the United States:
updated statistics from government health surveillance studies.
Headache. 2015;55:21–34.
9. Krishnamurthi RV, Moran AE, Feigin VL, Barker-Collo S,
Norrving B, Mensah GA, et al. Stroke prevalence, mortality and
disability-adjusted life years in adults aged 20-64 years in 1990-
2013: data from the Global Burden of Disease 2013 Study.
Neuroepidemiology. 2015;45:190–202.
10. Lee MJ, Lee C, Chung CS. The migraine-stroke connection. J
Stroke. 2016;18:146–56.
11. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovas-
cular disease. Curr Cardiol Rep. 2014;16:524.
12. Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH,
JohannssonM, Thorgeirsson G, et al. Migraine with aura and risk
of cardiovascular and all cause mortality in men and women:
prospective cohort study. BMJ. 2010;341:3966.
13. Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ,
Rimm EB, et al. Migraine and risk of cardiovascular disease in
women: prospective cohort study. BMJ. 2016;353:2610.
14. Wang YC, Lin CW, Ho YT, Huang YP, Pan SL. Increased risk of
ischemic heart disease in young patients with migraine: a popula-
tion-based, propensity score-matched, longitudinal follow-up
study. Int J Cardiol. 2014;172:213–6.
15. O'Keeffe ST, Tsapatsaris NP, Beetham Jr WP. Association be-
tween Raynaud's phenomenon and migraine in a random popula-
tion of hospital employees. J Rheumatol. 1993;20:1187–8.
16. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and
hemorrhagic stroke: a meta-analysis. Stroke. 2013;44:3032–8.
17. Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: a
review of the evidence and potential implications for management.
Cephalalgia. 2012;32:785–95.
18. Gaist D, González-Pérez A, Ashina M, Rodríguez LA. Migraine
and risk of hemorrhagic stroke: a study based on data from general
practice. J Headache Pain. 2014;15:74.
19. Malik R, Freilinger T, Bendik S, Winsvold BS, Anttila V, Vander
Heiden J, et al. Shared genetic basis for migraine and ischemic
stroke. A genome-wide analysis of common variants. Neurology.
2015;84:2132–45.
20. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T.
Migraine and cardiovascular disease: systematic review and meta-
analysis. BMJ. 2009;339:3914.
21. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic
stroke in people with migraine: systematic review and meta-
analysis of observational studies. BMJ. 2005;330:63.
22. Spector JT, Kahn SR, JonesMR, JayakumarM, Dalal D, Nazarian
S. Migraine headache and ischemic stroke risk: an updated meta-
analysis. Am J Med. 2010;123:612–24.
23. Kurth T, Chabriat H, Bousser MG. Migraine and stroke: a com-
plex association with clinical implications. Lancet Neurol.
2012;11:92–100.
24. De Falco FA, de Falco A. Migraine with aura: which patients are
most at risk of stroke? Neurol Sci. 2015;36:57–60.
25. MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell
BD, et al. Probable migraine study. Stroke. 2007;38:2438–45.
26. Norton J, Portet F, Gabelle A, Debette S, Ritchie K, Touchon J,
et al. Are migraine and non-migrainous headache risk factors for
stroke in the elderly? Findings from a 12-year cohort follow-up.
Eur J Neurol. 2016;23:1463–70.
27. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari
MD. Migraine is associated with an increased risk of deep white
matter lesions, subclinical posterior circulation infarcts and brain
iron accumulation. The population-based MRI CAMERA-study.
Cephalalgia. 2010;30:129–36.
28. Wolf ME, Szabo K, Griebe M, Förster A, Gass A, Hennerici MG,
et al. Clinical and MRI characteristics of acute migrainous infarc-
tion. Neurology. 2011;76:1911–7.
29. Olesen J. Headache classification committee of the international
headache society (IHS). The international classification of head-
ache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:
629–808.
30. Laurell K, Artto V, Bendtsen L, Hagen K, Kallela M, Meyer EL,
et al. Migrainous infarction: a Nordic multicenter study. Eur J
Neurol. 2011;18:1220–6.
31. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A,
Aspelund T, Eiriksdottir G. Migraine headache in middle age
and late-life brain infarcts. JAMA. 2009;301:2563–70.
32. Vincent M, Hadjikhani N. The cerebellum and migraine.
Headache. 2007;47:820–33.
33. Porter A, Gladstone JP, Dodick DW. Migraine and white matter
hyperintensities. Curr Pain Headache Rep. 2005;9:289–93.
34. Gladstone JP, Dodick DW. Migraine and cerebral white matter
lesions: when to suspect cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL).
Neurologist. 2005;11:19–29.
35. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structur-
al changes in the brain: a systematic review and meta-analysis.
Neurology. 2013;81:1260–8.
36. Rist PM, Dufouil C, Glymour MM, Tzourio C, Kurth T. Migraine
and cognitive decline in the population-based EVA study.
Cephalalgia. 2011;31:1291–300.
37. Eikermann-Haerter K. Spreading depolarization may link mi-
graine and stroke. Headache. 2014;54:1146–57.
38. Stam AH, Haan J, van den Maagdenberg AM, Ferrari MD,
Terwindt GM. Migraine and genetic and acquired vasculopathies.
Cephalalgia. 2009;29:1006–17.
39. Bigal ME, Kurth T, Santanello N, Buse D, GoldenW, RobbinsM,
et al. Migraine and cardiovascular disease: a population-based
study. Neurology. 2010;74:628–35.
40. SchürksM, Buring JE, Ridker PM, Chasman DI, Kurth T. Genetic
determinants of cardiovascular events among women with mi-
graine: a genome-wide association study. PLoS One. 2011;6:
22106.
41. Artto V,Metso TM,MetsoAJ, Putaala J, Haapaniemi E,Wessman
M, et al. Migraine with aura is a risk factor for cervical artery
dissection: a case-control study. Cerebrovasc Dis. 2010;30:36–40.
42. Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in
migraine pathogenesis. Neurol Sci. 2006;27:107–10.
43. Tietjen GE. Migraine as a systemic disorder. Neurology. 2007;68:
1555–6.
44. Eikermann-Haerter K, Ayata C. Cortical spreading depression and
migraine. Curr Neurol Neurosci Rep. 2010;10:167–73.
Curr Neurol Neurosci Rep (2017) 17: 22 Page 5 of 7 22
45. Ayata C, Lauritzen M. Spreading depression, spreading depolar-
izations, and the cerebral vasculature. Physiol Rev. 2015;95:953–
93.
46. Lauritzen M, Strong AJ. Spreading depression of Leão' and its
emerging relevance to acute brain injury in humans. J Cereb
Blood Flow Metab. 2016.
47. Kazemi H, Speckmann EJ, Gorji A. Familial hemiplegic migraine
and spreading depression. Iran J Child Neurol. 2014;8:6–11.
48. Tietjen EG. Migraine and ischaemic heart disease and stroke: po-
tential mechanisms and treatment implications. Cephalalgia.
2007;27:981–7.
49. Gursoy-Ozdemir Y, Qiu J,MatsuokaN, Bolay H, Bermpohl D, Jin
H, et al. Cortical spreading depression activates and upregulates
MMP-9. J Clin Invest. 2004;113:1447–55.
50. Piilgaard H, Lauritzen M. Persistent increase in oxygen consump-
tion and impaired neurovascular coupling after spreading depres-
sion in rat neocortex. J Cereb Blood Flow Metab. 2009;29:1517–
27.
51. Somjen GG. Mechanisms of spreading depression and hypoxic
spreading depression- like depolarisation. Physiol Rev. 2001;81:
1065–9.
52. Seitz I, Dirnagl U, Lindauer U. Impaired vascular reactivity of
isolated rat middle cerebral artery after cortical spreading depres-
sion in vivo. J Cereb Blood Flow Metab. 2004;24:526–30.
53. Bigal ME. Migraine and cardiovascular disease. Arq
Neuropsiquiatr. 2011;69:122–9.
54. Dreier JP. The role of spreading depression, spreading depolariza-
tion and spreading ischemia in neurological disease. Nat Med.
2011;17:439–47.
55. Tietjen GE. Circulating microparticles in migraine with aura:
cause or consequence, a link to stroke. Cephalalgia. 2015;35:85–
7.
56. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y,
Sakthisekaran D, Sethi G, et al. The vascular endothelium and
human diseases. Int J Biol Sci. 2013;9:1057–69.
57. Liman TG, Bachelier-Walenta K, Neeb L, Rosinski J, Reuter U,
Böhm M, et al. Circulating endothelial microparticles in female
migraineurs with aura. Cephalalgia. 2015;35:88–94.
58. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder
SA. Migraine and biomarkers of endothelial activation in young
women. Stroke. 2009;40:2977–82.
59. Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J,
Leira R. Endothelial progenitor cells: a new key for endothelial
dysfunction in migraine. Neurology. 2012;79:474–9.
60. Vernieri F, Tibuzzi F, Pasqualetti P, Altamura C, Palazzo P, Rossini
PM, et al. Increased cerebral vasomotor reactivity inmigraine with
aura: an autoregulation disorder? A transcranial Doppler and near-
infrared spectroscopy study. Cephalalgia. 2008;28:689–95.
61. Akin A, Bilensoy D. Cerebrovascular reactivity to hypercapnia in
migraine patients measured with near- infrared spectroscopy.
Brain Res. 2006;1107:206–14.
62. Rajan R, Khurana D, Lal V. Interictal cerebral and systemic endo-
thelial dysfunction in patients with migraine: a case-control study.
J Neurol Neurosurg Psychiatry. 2015;86:1253–7.
63. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari
MD, Launer LJ. Cardiovascular risk factors and migraine: the
GEM population-based study. Neurology. 2005;64:614–20.
64. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects
of hypertension on the cerebral circulation. Am J Physiol Heart
Circ Physiol. 2013;304:1598–614.
65. Ikeda K, Kawase Y, Takazawa T, Kano O, Tamura M, Iwasaki Y.
Cardiovascular disease risk profile in Japanese midlife
migraineurs. J Neurol Res. 2012;2:10–5.
66. Gardener H,Monteith T, Rundek T,Wright CB, ElkindMS, Sacco
RL. Hypertension and Migraine in the NorthernManhattan Study.
Ethn Dis. 2016;26:323–30.
67. Tronvik E, Zwart JA, Hagen K, et al. Association between blood
pressure measures and recurrent headache in adolescents: cross-
sectional data from the HUNT Youth study. J Headache Pain.
2011;12:347–53.
68. Hagen K, Stovner LJ, Vatten L, Holmen J, Zwart JA, Bovim G.
Blood pressure and risk of headache: a prospective study of 22,
685 adults in Norway. J Neurol Neurosurg Psychiatry. 2002;72:
463–6.
69. Queiroz LP, Peres MF, Piovesan EJ, Kowacs F, Ciciarelli MC,
Souza JA, et al. A nationwide population-based study of migraine
in Brazil. Cephalalgia. 2009;29:642–9.
70. Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, et al.
Migraine and bodymass index categories: a systematic review and
meta-analysis of observational studies. J Headache Pain. 2015;16:
27.
71. Ligong Z, Jinjin Q, Chunfu C, Congcong L, Xiaojun D. Effect of
obesity and leptin level on migraineurs. Med Sci Monit. 2015;21:
3270–4.
72. Winsvold BS, Hagen K, Aamodt AH, Stovner LJ, Holmen J,
Zwart JA. Headache, migraine and cardiovascular risk factors:
The HUNT study. Eur J Neurol. 2011;18:504–11.
73. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J.
Association between migraine, lifestyle and socioeconomic fac-
tors: a population-based cross-sectional study. J Headache Pain.
2011;12:157–72.
74. Sacco S, Pistoia F, Degan D, Carolei A. Conventional vascular
risk factors: their role in the association between migraine and
cardiovascular diseases. Cephalalgia. 2015;35:146–64.
75. Rozen TD. A history of cigarette smoking is associated with the
development of cranial autonomic symptoms with migraine head-
aches. Headache. 2011;51:85–91.
76. Taylor FR. Tobacco, nicotine, and headache. Headache. 2015;55:
1028–44.
77. Hozawa A, Houston T, Steffes MW, Widome R, Williams OD,
Iribarren C, et al. The association of cigarette smoking with self-
reported disease before middle age: the Coronary Artery Risk
Development in Young Adults (CARDIA) study. Prev Med.
2006;42:193–9.
78. Rockett FC, Perla Ada S, Perry ID, Chaves ML. Cardiovascular
disease risk in women with migraine. J Headache Pain. 2013;14:
75.
79. Katsarava Z, Weimar C. Migraine and stroke. J Neurol Sci.
2010;299:42–4.
80. Zier LS, Sievert H, Mahadevan VS. To close or not to close:
contemporary indications for patent foramen ovale closure.
Expert Rev Cardiovasc Ther. 2016;10:1–10.
81. Taramasso M, Nietlispach F, Maisano F, Meier B. Patent foramen
ovale: indications for closure and techniques. EuroIntervention.
2016;12:7–12.
82. Kahya Eren N, Bülbül NG, Yakar Tülüce S, Nazlı C, Beckmann
Y. To be or not to be patent: the relationship between migraine and
patent foramen ovale. Headache. 2015;55:934–42.
83. Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen
ovale and migraine: a quantitative systematic review.
Cephalalgia. 2008;28:531–40.
84. Ailani J. Migraine and patent foramen ovale. Curr Neurol
Neurosci Rep. 2014;14:426.
85. Larrosa D, Ramón C, Alvarez R, Martínez-Camblor P, Cernuda E,
Pascual J. No relationship between patent foramen ovale and mi-
graine frequency. Headache. 2016;56:1466–73.
86. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C,
et al. Migraine Intervention With STARFlex Technology (MIST)
trial: a prospective, multicenter, double-blind, sham-controlled tri-
al to evaluate the effectiveness of patent foramen ovale closure
with STARFlex septal repair implant to resolve refractory mi-
graine headache. Circulation. 2008;117:1397–404.
22 Page 6 of 7 Curr Neurol Neurosci Rep (2017) 17: 22
87. Lantz M, Kostulas K, Waldenlind E, Sjöstrand C. Prevalence of
migraine headache in an in-patient stroke population. Acta Neurol
Scand. 2015;131:290–7.
88. Butera G, Biondi-Zoccai GG, Carminati M, Caputi L, Usai S,
BussoneG, et al. Systematic review andmeta-analysis of currently
available clinical evidence on migraine and patent foramen ovale
percutaneous closure: much ado about nothing? Catheter
Cardiovasc Interv. 2010;75:494–504.
89. Papa M, Gaspardone A, Fragasso G, Ajello S, Gioffrè G, Iamele
M, et al. Usefulness of transcatheter patent foramen ovale closure
in migraineurs with moderate to large right-to-left shunt and in-
strumental evidence of cerebrovascular damage. Am J Cardiol.
2009;104:434–9.
90. Chessa M, Colombo C, Butera G, Negura D, Piazza L, Varotto L,
et al. Is it too early to recommend patent foramen ovale closure for
all patients who suffer from migraine? A single-centre study. J
Cardiovasc Med. 2009;10:401–5.
91. Wahl A, Praz F, Tai T, Findling O,Walpoth N, Nedeltchev K, et al.
Improvement of migraine headaches after percutaneous closure of
patent foramen ovale for secondary prevention of paradoxical em-
bolism. Heart. 2010;96:967–73. doi:10.1136/hrt.2009.181156.
92. Finocchi C, Del Sette M. Migraine with aura and patent foramen
ovale: myth or reality? Neurol Sci. 2015;36:61–6.
93. Tobis J, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz
PA, et al. TCT-30 PREMIUM Trial: Double blind study of percu-
taneous closure of patent foramen ovale with the AMPLATZER®
PFO Occluder as a treatment for migraine with or without aura. J
Am Coll Cardiol 2015;66.
94. Malik R, Freilinger T, Winsvold BS, Anttila V, Vander Heiden J,
Traylor M, et al. Shared genetic basis for migraine and ischemic
stroke: a genome-wide analysis of common variants. Neurology.
2015;84:2132–45.
95. Zhu S, Nahas SJ. CADASIL: imaging characteristics and clinical
correlation. Curr Pain Headache Rep. 2016;20:57.
96. Moreton FC, Razvi SS, Davidson R, Muir KW. Changing clinical
patterns and increasing prevalence in CADASIL. Acta Neurol
Scand. 2014;130:197–203.
97. Yamamoto Y, Craggs LJ, Watanabe A, Booth T, Attems J, Low
RW, et al. Brain microvascular accumulation and distribution of
the NOTCH3 ectodomain and granular osmiophilic material in
CADASIL. J Neuropathol Exp Neurol. 2013;72:416–31.
98. Silberstein SD, Lipton RB, Dalessio DJ. Wolff’s Headache and
other head pain. In: Silberstein SD, Saper JR, Freitag FG, editors.
Migraine: diagnosis and treatment. Oxford: Oxford University
Press; 2001.
99. Stojanov D, Vojinovic S, Aracki-Trenkic A, Tasic A, Benedeto-
Stojanov D, Ljubisavljevic S, et al. Imaging characteristics of
cerebral autosomal dominant arteriopathy with subcortical infarcts
and leucoencephalopathy (CADASIL). Bosn J Basic Med Sci.
2015;15:1–8.
100. Fan C, Wolking S, Lehmann-Horn F, Hedrich UB, Freilinger T,
Lerche H. Early-onset familial hemiplegic migraine due to a novel
SCN1A mutation. Cephalalgia. 2016.
101. Weng TH, Chiu WT, Afilalo M, Choy CS, Tselios C, Yip PK. A
young man presenting with acute encephalopathy, hemiparesis,
and headache. J Emerg Med. 2012;43:258–62.
102. Eikermann-Haerter K, Lee JH, Yuzawa I, Liu CH, Zhou Z, Shin
HK. Migraine mutations increase stroke vulnerability by facilitat-
ing ischemic depolarizations. Circulation. 2012;125:335–45.
103. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L,
D'Alessandro R. Adverse cardiovascular events associated with
triptans and ergotamines for treatment of migraine: systematic
review of observational studies. Cephalalgia. 2015;35:118–31.
104. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier
CR. Migraine and the risk of stroke, TIA, or death in the UK
(CME). Headache. 2007;47:1374–84.
105. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vas-
cular events in migraine patients. Headache. 2004;44:642–51.
106. Martin VT, Goldstein JA. Evaluating the safety and tolerability
profile of acute treatments for migraine. Am J Med. 2005;118:
36–44.
107. Faubion SS, Casey PM, Shuster LT. Hormonal contraception and
migraine: clinical considerations. Curr Pain Headache Rep.
2012;16:461–6.
108. Calhoun AH. Hormonal contraceptives and migraine with aura—
Is there still a risk? Headache. 2016.
109. Calhoun A. Combined hormonal contraceptives: is it time to reas-
sess their role in migraine? Headache. 2012;52:648–60.
110. Martin VT, Behbehani M. Ovarian hormones and migraine head-
ache: understanding mechanisms and pathogenesis—part 2.
Headache. 2006;46:365–86.
111. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T.
Migraine and cardiovascular disease: systematic review and meta-
analysis. BMJ. 2009;339:3914.
112. Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal
ring contraception on migraine aura: a retrospective case series.
Headache. 2012;52:1246–53.
113. Silberstein SD, Lipton RB, Dalessio DJ. Wolff’s Headache and
other head pain. In: Bousser MG, Good J, Kittner SJ, Silberstein
SD, editors. Headache associated with vascular disorders. Oxford:
Oxford University Press; 2001.
114. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC,
Buring JE. Migraine and risk of cardiovascular disease in women.
JAMA. 2006;296:283–91.
Curr Neurol Neurosci Rep (2017) 17: 22 Page 7 of 7 22
